Precision BioSciences, Inc. (DTIL)
NASDAQ: DTIL · Real-Time Price · USD
5.56
-0.06 (-1.07%)
At close: Oct 13, 2025, 4:00 PM EDT
5.65
+0.09 (1.62%)
After-hours: Oct 13, 2025, 6:26 PM EDT
Precision BioSciences Revenue
Precision BioSciences had revenue of $18.00K in the quarter ending June 30, 2025, a decrease of -99.96%. This brings the company's revenue in the last twelve months to $1.26M, down -98.56% year-over-year. In the year 2024, Precision BioSciences had annual revenue of $68.70M with 40.98% growth.
Revenue (ttm)
$1.26M
Revenue Growth
-98.56%
P/S Ratio
39.30
Revenue / Employee
$11,676
Employees
108
Market Cap
65.54M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 68.70M | 19.97M | 40.98% |
| Dec 31, 2023 | 48.73M | 23.63M | 94.15% |
| Dec 31, 2022 | 25.10M | -90.43M | -78.28% |
| Dec 31, 2021 | 115.53M | 91.24M | 375.72% |
| Dec 31, 2020 | 24.29M | 2.05M | 9.20% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
DTIL News
- 4 days ago - Precision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for High Efficiency Gene Insertion in Dividing and Non-Dividing Cells Using ARCUS Nucleases - Business Wire
- 6 days ago - Precision BioSciences Announces Opening of First Clinical Trial Site in U.S. for ELIMINATE-B Trial - Business Wire
- 13 days ago - Precision BioSciences Announces Late-Breaking Poster Presentation at the 30th Annual International Congress of the World Muscle Society - Business Wire
- 27 days ago - Precision BioSciences, Inc. (DTIL) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript - Seeking Alpha
- 4 weeks ago - Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium - Business Wire
- 5 weeks ago - Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program Status - Business Wire
- 2 months ago - Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 2 months ago - Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B - Business Wire